Liquid Chromatography development for determination of ebastine in pharma
A new method has been developed for determining ebastine in pharma preparations

HPLC, UHPLC

Liquid Chromatography development for determination of ebastine in pharma

12 May, 2011

Published over 15 years ago. See the latest and most current information on HPLC, UHPLC.

Scientists have developed a new method for determining ebastine in its pharmaceutical preparations, according to 7th Space Interactive.

The news source reported that this model depends on the complexation ability of the studied drug with Zn2+ ions.
Reversed phase chromatography was carried out using an ODS c18 stainless steel column with UV-detection at 260nm.

Furthermore, a mobile phase containing 0.025 per cent w/v Zn2+ in a mixture of (acetonitril/methanol) and Britton Robinson buffer, which was adjusted to a pH of 4.2, was used to determine the ebastine at a flow rate of one ml/min.

It was also reported that content uniformity testing of the method was also conducted, while the make-up of the complex and its stability constant was looked into.

Recently, liquid chromatography was used to analyse endometrial hyperplasia and carcinoma, with findings published in the Journal of Hematology and Oncology, highlighting that these gynaecological malignancies are the most common.

Latest News

Explore Our Other Sites

Labmate Online
Lab-grown kidney organoids set to recast research landscape into kidney disease
Explore more Arrow
Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow